Compare Humana Inc (HUM) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs T-Mobile Us Inc — how do they compare? Humana Inc trades at $374.25 (market cap $46.31B), while T-Mobile Us Inc trades at $178.13 (market cap $191.15B). The key difference: T-Mobile Us Inc is far larger — about 4.1× Humana Inc's market cap, and T-Mobile Us Inc pays the higher dividend (2.29%). Which is the better fit depends on your goals.
| HUM | TMUS | |
|---|---|---|
Market Cap | $46.31B | $191.15B |
Sector | Health | Media |
52-Week High | $409.42 | $259.01 |
52-Week Low | $163.67 | $167.65 |
Enterprise Value | $53.67B | $307.76B |
Dividend Yield | 0.92% | 2.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $385.00, up 4.82% today, with a bullish technical outlook and analyst consensus price target of $399.53. Recent earnings beats in Q1 and Q2 2026, alongside revenue growth to $129.66 billion in 2025, support fundamentals, though net margins have compressed. The company is expanding its Medicaid business and targeting margin improvements by 2027.
The stock offers upside to consensus targets but faces risks from Medicare Advantage margin pressures and regulatory changes. Profitability trends are weak despite revenue growth, requiring successful cost management to meet 2028 targets. Institutional sentiment is mixed with a majority hold rating.
T-Mobile US (TMUS) trades at $177.19, down 1.54% over 24 hours, amid a bearish technical signal and recent volatility. The company reported strong Q2 2026 earnings with a beat on EPS of $2.99 versus $2.59 expected, alongside revenue growth and raised cash flow guidance. However, technical indicators show selling pressure, with support at $176 and resistance at $179. Valuation metrics include a P/E of 18.53 and P/S of 2.13, while profitability remains robust with a net income margin of 11.45%.
The outlook for TMUS is mixed; strong fundamentals and an 81% analyst buy rating support upside to a $233.20 consensus target, but risks include competitive threats from SpaceX's Starlink and technical bearishness. Investors should weigh solid execution against near-term headwinds for potential long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
